T‐cell‐mediated hypersensitivity to lumacaftor and ivacaftor in cystic fibrosis.

Cystic fibrosis (CF) is a serious genetic condition affecting the respiratory and digestive systems impacting life expectancy.1 Patients with CF often require frequent high-dose antibiotics associated with cutaneous hypersensitivity in 30%-50% of patients.2 The discovery of cystic fibrosis transmembrane regulator (CFTR) modulators has transformed CF treatment. Keywords: cystic fibrosis (CF); Cystic fibrosis transmembrane regulator (CFTR); Drug related eosinophilia with systemic symptoms (DRESS); interferon-gamma ELIspot; lymphocyte transformation test EN cystic fibrosis (CF) Cystic fibrosis transmembrane regulator (CFTR) Drug related eosinophilia with systemic symptoms (DRESS) interferon-gamma ELIspot lymphocyte transformation test 1 4 4 06/29/22 20220601 NES 220601 PEER REVIEW The peer review history for this article is available at https://publons.com/publon/10.1111/pai.13815. Cystic fibrosis (CF), Cystic fibrosis transmembrane regulator (CFTR), Drug related eosinophilia with systemic symptoms (DRESS), interferon-gamma ELIspot, lymphocyte transformation test. [Extracted from the article]